Helico aims to become a fully integrated biopharmaceutical company that improves access to therapies where there are global supply shortages or unmet production needs. Our work evolves in the area of advanced computational science and plant biology, leading to expression and the production of proteins, antibodies, and enzymes in host plants. Helico’s business model aims to use the proprietary BioVerge expression platform to deliver rapid, cost-effective biologics manufacturing.
First, we assess the compound of interest using Helico’s proprietary computational algorithms. Specifically trained on biological data, the model greatly speeds up geneticwork in plants. The target is then evaluated in the lab with HTS models based on transient expression. Once the target is validated, we move to the generation of stable lines, the final deliverable. What’s more, we’re developing extraction and purification methods to achieve the best commercial yields based on our clients' specifications.
Protein yield is optimised using AI-based gene design, SeqOptima
Expression targeted wet lab experiments using enhanced plant strain, Verdantix
Plants as the production model makes scalability easy and adaptable
